PDF Cohorts
01 / 14

TriStar Technology Group

Quality biospecimens,
imaging & data for
precision medicine

FFPE surgical samples — Primary tumors, Mets, Normal (non-malignant) tissues

Donors from UK, Italy, France with informed consent & ethics approval

Clinical follow-up data including treatment, response, OS & PFS

Responders & non-responders to SOC treatment including CKI/IO

Mutations, fusions and other diagnostic markers

Expert IHC capabilities — over 100 optimized assays

02 / 14

Imaging + Clinical Data.

Whole-slide imaging tied back to the matched surgical section and the clinical timeline behind every donor. Radiology coming soon.

Radiology Coming soon Radiological images — capability in development.

Pathology

Whole-slide imaging (WSI)

Current H&E repository

30,000

donors

>100,000

H&E images

  • Aperio GT450 & AT2 scanners — same platforms used in clinical practice
  • 40× standard scan resolution across the repository
  • .svs files compatible with all major WSI viewers and AI pipelines
  • Scanned in-house — no vendor coordination, no provenance gaps
  • Pathologist-reviewed — every H&E and corresponding image checked by an experienced medical pathologist to confirm image quality is suitable for AI

Linkage

Every imaging asset is linked to

Imaging Whole-slide imaging
Surgical section Matched FFPE block & slides
Clinical data Treatment, response, OS/PFS, molecular
03 / 14

Breadth of donor profiles.

Specimen, treatment, outcomes, and molecular data — structured at the patient level.

Patient trajectory

Primary & matched distant mets Matched normal tissue Neoadjuvant › adjuvant › SOC targeted & CKI/IO

Outcomes, structured

Overall Survival (months) Progression-Free Survival (months) Time to events (TTE months) Last follow-up Event flags (recurrence / death / composite)

Molecular characterization

IHC FISH RNA-ISH NGS: SNV, CNV, Fusions

Records are fully anonymized. Not every patient has every field populated, and not every project needs every field. Cohorts are pulled to fit the project; populated fields reflect real-world clinical practice at the source center.

See an example record
04 / 14

Cohorts available.

Tumor types by cohort designs we maintain.

Jump to cohort detail
Tumor type Advanced (III/IV) Longitudinal Primary + matched mets Pre / Post SOC Pre / Post IO
NSCLC ✓ ✓ ✓ ✓ ✓
CRC ✓ ✓ ✓ ✓ —
Ovarian ✓ ✓ ✓ ✓ —
Breast ✓ ✓ ✓ ✓ —
Gastric ✓ ✓ ✓ ✓ —
Head & Neck SCC ✓ ✓ ✓ ✓ ✓
Prostate (mCRPC) ✓ ✓ — ✓ —
Endometrial ✓ ✓ ✓ ✓ —
Pancreatic ADC ✓ — — ✓ —
Bladder (UC) ✓ ✓ ✓ ✓ —
Melanoma ✓ ✓ ✓ ✓ ✓
RCC ✓ ✓ ✓ ✓ ✓
HCC ✓ ✓ ✓ ✓ —
Esophageal ✓ ✓ ✓ ✓ —

All cohorts are available as FFPE, TMA, or slides. Treatment, response, OS/PFS data and indication-specific molecular characterization (IHC and mutation panels) are linked at the patient level.

05 / 14

A core partner for translational programs.

Why top pharma and biotechs working on oncology therapeutics work with us.

  • The translational bar has moved. Sponsors developing oncology therapeutics need high-quality samples paired with in-depth, standardized data across EHR and orthogonal sources.
  • Ethically sourced, quality samples and data. Quality samples and data improve the reliability of results.
  • Validation for regulators. Data derived from TriStar samples is frequently included in IND submissions — tissue quality and annotation rigor shape what is defensible.
  • Validation for the program. Translational evidence is increasingly what investment committees and partnership negotiations anchor on.
  • Translational evidence is increasingly the rate-limiting step. Tissue quality, annotation depth, and provenance decide whether downstream analysis withstands scientific and regulatory scrutiny.
06 / 14

Lab capabilities — validation, extension & characterization.

Run in-house on the same donors and samples behind every cohort — no vendor coordination, no provenance gaps.

100+ Optimized IHC assays
Developed for
  • Ventana Benchmark
  • Dako autostainers
3 Medical pathologists 15+ combined years in pharma
Services
  • IHC
  • RNAScope
  • NGS
  • RNA-Seq
  • Digital Spatial Profiling
  • Digital image analysis
07 / 14

Advanced disease (Stage III/IV) surgical samples

Approximate number of donors

500–900 per tumor type

Tumor types

NSCLC CRC Ovarian Prostate (mCRPC) Breast Gastric Endometrial Pancreatic ADC Bladder (UC) Melanoma RCC HCC Esophageal Head & Neck SCC

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
Example HBS Cohorts & Data Available
08 / 14

Sequentially collected (longitudinal) surgical samples from the same donor

Approximate number of donors

20–70 sets per indication

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial RCC Bladder (UC) Melanoma

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
Example HBS Cohorts & Data Available
09 / 14

Longitudinal Example: NSCLC.

Per-patient. Per matched metastasis. Treatment-line resolved. Examples below are anonymized records from the repository.

Patient #001 Immunotherapy: NoTreatment status: Treatment naïve
  1. Primary specimen Surgery: Left lung upper lobectomy and lymph node sampling Site: Lung, left upper lobe
  2. Matched met 1 Site: Superficial cerebrum and dura Treatment: Immunotherapy naïve
Patient #002 Immunotherapy: NoTreatment status: Treatment naïve
  1. Primary specimen Surgery: Left Thoracotomy and upper lobectomy with wedge of the lower lobe taken en bloc. Sleeve resection of PA Site: Left lung, upper lobe
  2. Matched met 1 Site: Lymph node Treatment: Treatment naïve
  3. Matched met 2 Site: Lymph node Surgery date: Q1-2018 Treatment: Treatment naïve
Patient #007 Immunotherapy: No
  1. Matched met 1 Site: Lymph node Treatment: Treatment naïve
  2. Matched met 2 Site: Lymph node Treatment: Treatment naïve
  3. Matched met 3 Site: Hilar Lymph node Surgery date: Q1-2022 Treatment: Treatment naive Block #: C7
Example HBS Cohorts & Data Available
10 / 14

Primary & matched distant metastases (surgical samples)

Approximate number of donors

20–50 sets per indication

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial Bladder (UC) Melanoma RCC

Examples of metastatic sites

Lymph nodes Bone Liver Lung Brain Peritoneal

*Mets only (without matched primary) samples available

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

*As available from donor records.

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE Slides TMA Block or slides
Example HBS Cohorts & Data Available
11 / 14

Pre & Post standard of care (SOC) treatment surgical samples

Includes a sub-set of donor matched sets.

Approximate number of donors

25–150 per indication

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial Pancreatic ADC Bladder (UC) Melanoma RCC

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
Example HBS Cohorts & Data Available
12 / 14

Pre & Post IO (Pembro/Nivo) treatment surgical samples

1st line SOC chemo, 2nd line IO. Includes a sub-set of donor matched sets.

Approximate number of donors

10–25 per indication

Tumor types

NSCLC RCC Head & Neck SCC Melanoma

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE Slides TMA Block or slides
Example HBS Cohorts & Data Available
13 / 14

FFPE blocks & TMAs with matched double-spun plasma.

FFPE block & 4ml matched double-spun plasma or whole blood.

~330

Total sample sets

8

Indications

40 / 60

Stage I–II / III–IV (%)

5–20min

Ischemic time

Indication FFPE blocks Plasma / blood NGS-eligible†
NSCLC50●●
CRC100●●
Gastric ADC30●●
RCC30●●
Esophageal cancer40●●
Endometrial cancer50●●
Ovarian cancer20●●
Melanoma10●●

Compatible assays

IHC RNA-ISH NGS (Oncomine)

† NGS (Oncomine) panel can be ordered separately on any indication.

Note — these sets do not have outcome data and were collected from Ukraine.

Quantities are approximate and subject to change.

Example HBS Cohorts & Data Available